- |||||||||| ALLO-715 / Allogene Therap
Enrollment closed, Trial completion date, Trial primary completion date, CAR T-Cell Therapy, IO biomarker: Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (clinicaltrials.gov) - Aug 14, 2023 P1, N=132, Active, not recruiting, Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Dec 2022 --> Sep 2027 | Recruiting --> Active, not recruiting
- |||||||||| ALLO-647 / Allogene Therap, ALLO-715 / Allogene Therap
P1 data, Clinical Trial,Phase I, Journal, CAR T-Cell Therapy: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. (Pubmed Central) - Feb 27, 2023 Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Dec 2022 --> Sep 2027 | Recruiting --> Active, not recruiting We evaluated escalating doses of ALLO-715 after lymphodepletion with an anti-CD52 antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoing first-in-human phase 1 UNIVERSAL trial...Among patients treated with 320?
- |||||||||| ALLO-715 / Allogene Therap
Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2888; P1 Pts receive LD followed by ALLO-715 at 1 of 4 dose levels (DLs) in a 3+3 dose escalation design: 40 (DL1), 160 (DL2), 320 (DL3), and 480 (DL4) x 106 CAR+ T cells with varying doses and schedules of LD including ALLO-647 with fludarabine and cyclophosphamide (FC)...The use of tocilizumab and steroids across all pts was 19% and 15%, respectively...FCA induces a deep and durable window of lymphocyte depletion allowing CAR T cell expansion. The UNIVERSAL trial continues to enroll pts in the FCA60 cohort and updated data will be presented.
- |||||||||| Review, Journal, CAR T-Cell Therapy: Current state and next-generation CAR-T cells in multiple myeloma. (Pubmed Central) - May 29, 2022
In light of those clinical data, we provide an overview of CAR-T cells' main potential resistance mechanisms, including antigen loss, antigen spreading, anti-CAR antibodies, CAR-T cell exhaustion, and the emergence of a non-permissive microenvironment. Finally, we describe the principal area of research to build the next generation of CAR-T cells, with armored-, gated- or commuting-CARs, CARs associated with knock out of specific genes, and CAR-T cells made from γδT cells or NK cells.
- |||||||||| ALLO-715 / Allogene Therap
Enrollment open, Trial completion date, Trial primary completion date, CAR T-Cell Therapy, IO biomarker: Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (clinicaltrials.gov) - Mar 7, 2022 P1, N=132, Recruiting, Finally, we describe the principal area of research to build the next generation of CAR-T cells, with armored-, gated- or commuting-CARs, CARs associated with knock out of specific genes, and CAR-T cells made from γδT cells or NK cells. Active, not recruiting --> Recruiting | Trial completion date: Nov 2024 --> Dec 2027 | Trial primary completion date: Nov 2021 --> Dec 2022
- |||||||||| ALLO-715 / Allogene Therap, Actemra IV (tocilizumab) / Roche, JW Pharma
Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma (GWCC - Sidney Marcus Auditorium, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_2114; P1 Several LD regimens are being evaluated: FCA39; FCA60; FCA90; and CA39; with fludarabine [F] 90 mg/m 2 , cyclophosphamide [C] 900 mg/m 2 , and ALLO-647 [A] 39, 60, or 90 mg divided over 3 days...CRS was treated with tocilizumab (21.3%) and corticosteroids (12.8%)...A study using the next generation anti-BCMA CAR (ALLO-605) which supplies cytokine signaling to the CAR bearing cells is ongoing (IGNITE). The current UNIVERSAL trial continues to enroll, including a cohort with consolidation, and updated data will be presented at the meeting.
- |||||||||| ALLO-715 / Allogene Therap
Enrollment closed, CAR T-Cell Therapy, IO biomarker: Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (clinicaltrials.gov) - Oct 14, 2021 P1, N=132, Active, not recruiting, The current UNIVERSAL trial continues to enroll, including a cohort with consolidation, and updated data will be presented at the meeting. Recruiting --> Active, not recruiting
- |||||||||| [VIRTUAL] BCMA-Directed CAR T-Cells: Early Results and Future Directions () - Sep 6, 2021 - Abstract #SOHO2021SOHO_389;
The initial results from the UNIVERSAL phase 1 study in RRMM are encouraging, with responses reported and more attenuated toxicity.26 Others, including CTX120, BCMAUCART, UCART CS1, and PBCAR269A, are in development and in early-phase studies...Despite these impressive results, however, patients with MM continue to relapse. Moving these therapies earlier in the course of the disease, continued refinement of next-generation products, and rational combination strategies that may defer or prevent relapse should continue to improve on these results with the goal of finally reaching that elusive cure.
- |||||||||| ALLO-715 / Allogene Therap, Cellectis, Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma (Channel 10 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1077; P1 These include: FCA (fludarabine (F) 90 mg/m2, cyclophosphamide (C) 900 mg/m2, and ALLO-647 (A) 39 mg divided over 3 days), FCA+ (same F and C but ALLO-647 (A+) dose of 90 mg divided over 3 days); as well as CA (same C and A divided over 3 days, but no F given)...Three episodes were Grade 1 and 1 was Grade 2 (Lee Grading); all resolved without tocilizumab or corticosteroids...Updated safety, efficacy, PK/PD data will be presented. Clinical trial information: NCT04093596.
|